2seventy bio (BMV:TSVT *) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

TSVT * Stoklara Genel Bakış

A cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States.

Şirket hakkında

TSVT * temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	1/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 15.99% oranında artması öngörülüyor

Risk Analizi

Hisse senetleri oldukça likit değildir

Hissedarlar geçen yıl sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

2seventy bio, Inc. Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$23.6b

BioNote

KOSE:A377740

₩466.4b

Adimmune

TWSE:4142

NT$10.8b

Fate Therapeutics

NasdaqGM:FATE

US$366.7m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti 2seventy bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$170.00
52 Haftanın En Yüksek Seviyesi	US$347.00
52 Haftanın En Düşük Seviyesi	US$167.00
Beta	0
11 Aylık Değişim	0%
3 Aylık Değişim	0%
1 Yıllık Değişim	-69.26%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-80.09%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	TSVT *	MX Biotechs	MX Pazar
7D	0%	0%	0%
1Y	-69.3%	0%	0%

Getiri vs. Endüstri: TSVT * geçen yıl % 16.2 oranında getiri sağlayan MX Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: TSVT * geçen yıl % 4.5 oranında getiri sağlayan MX Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is TSVT *'s price volatile compared to industry and market?
TSVT * volatility
TSVT * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

İstikrarlı Hisse Senedi Fiyatı: TSVT * son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: TSVT * 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2021	425	Nick Leschly	www.2seventybio.com

2seventy bio, Inc. Temel Bilgiler Özeti

2seventy bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
TSVT * temel i̇stati̇sti̇kler
Piyasa değeri	Mex$5.89b
Kazançlar(TTM)	-Mex$3.64b
Gelir(TTM)	Mex$2.11b

2.8x

P/S Oranı

-1.6x

F/K Oranı

TSVT * aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
TSVT * gelir tablosu (TTM)
Gelir	US$124.69m
Gelir Maliyeti	US$272.99m
Brüt Kâr	-US$148.30m
Diğer Giderler	US$67.16m
Kazançlar	-US$215.46m

Son Raporlanan Kazançlar

Mar 31, 2023

Sonraki Kazanç Tarihi

Aug 14, 2023

Hisse başına kazanç (EPS)	-4.29
Brüt Marj	-118.94%
Net Kâr Marjı	-172.80%
Borç/Özkaynak Oranı	0%

TSVT * uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

TSVT * Stoklara Genel Bakış

Ödüller

Risk Analizi

2seventy bio, Inc. Rakipler

BMV:LAB B

Mex$23.6b

KOSE:A377740

₩466.4b

TWSE:4142

NT$10.8b

NasdaqGM:FATE

US$366.7m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Recent updates

2seventy bio, Inc. to Report Q2, 2024 Results on Aug 07, 2024

2seventy bio, Inc., Annual General Meeting, Jun 10, 2024

2seventy bio, Inc. to Report Q1, 2024 Results on May 15, 2024

U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio’S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $15 million.

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

2seventy bio, Inc. Announces Board Appointments

FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy

2seventy bio, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study

2seventy bio, Inc. Announces Executive and Board Changes

Bristol Myers Squibb and 2seventy bio, Inc. Announce Results from the Preplanned Final Progression-Free Survival Analysis of KarMMa-3

Bristol Myers Squibb and 2seventy bio, Inc Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Early Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma

2seventy bio, Inc. Announces Goodwill Impairment Charges for the Third Quarter Ended September 30, 2023

2seventy bio, Inc. to Report Q3, 2023 Results on Nov 14, 2023

2seventy bio, Inc. Plans to Reduce its Workforce by Approximately 40%

2Seventy Bio, Inc. Announces That Chip Baird Is Now Chief Operating Officer Expanding His Responsibilities to Include Finance, Corporate Development, Investor Relations and Corporate Communications as Well as Portfolio and Program/Alliance Management

2seventy bio, Inc. to Report Q2, 2023 Results on Aug 14, 2023

2seventy bio Announces Clinical Study Pause of PLAT-08 Trial of SC-DARIC33 in Acute Myeloid Leukemia

First quarter 2023 earnings released: US$1.08 loss per share (vs US$3.20 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Bristol Myers Squibb and 2Seventy Bio Announce the First Publication and Presentation of Positive Results from KarMMa-3

2Seventy Bio, Inc Announces Resignation of Nicola Heffron as Chief Operating Officer, Effective as of March 10, 2023

High number of new and inexperienced directors

President recently sold Mex$590k worth of stock

2seventy bio, Inc. announced that it has received $19.999996 million in funding from Regeneron Pharmaceuticals, Inc.

High number of new and inexperienced directors

2Seventy Bio, Inc. to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

2Seventy Bio Announces Plans to Initiate KarMMa-9 Study of Abecma (Idecabtagene Vicleucel) in Newly Diagnosed Multiple Myeloma Patients

Second quarter 2022 earnings released: US$2.02 loss per share (vs US$3.60 loss in 2Q 2021)

Bristol Myers Squibb and 2seventy bio, Inc. Announce Topline Results from KarMMa-3

President recently sold Mex$1.8m worth of stock

President recently sold Mex$1.5m worth of stock

High number of new and inexperienced directors

2Seventy Bio, Inc. Announces Resignation of William Sellers to Its Board of Directors

High number of new and inexperienced directors

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

2seventy bio, Inc. Temel Bilgiler Özeti

2.8x

-1.6x

Kazanç ve Gelir